Ampliphi Biosciences Corp (APHB) 0.3050 $APHB
Retinal Degeneration - Pipeline Review, H1 2014
M2 - Wed Jul 30, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3mjdx6/retinal) has announced the addition of the "Retinal Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Degeneration - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Degeneration and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Mentioned: - AmpliPhi Biosciences Corporation - SanBio, Inc. - to-BBB technologies BV - Aprogen, Inc. - X-BODY BioSciences, Inc. - GenSight Biologics - Spark Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/3mjdx6/retinal
AmpliPhi to Present at 13th Annual Needham Healthcare Conference
Business Wire - Tue Apr 01, 7:01AM CDT
AmpliPhi BioSciences Corporation. (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that Philip Young, President and CEO, will be presenting a corporate overview at the 13th Annual Needham Healthcare Conference on Tuesday, April 08 at 8:40am EDT at the Westin NY Grand Central Hotel in New York, NY.
AmpliPhi to Present at Upcoming Healthcare Conferences
Business Wire - Wed Feb 26, 6:30AM CST
AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34th Annual Healthcare Conference at the Boston Marriott Copley Place Hotel in Boston at 2:50 pm EST (11:50 am PST) on Monday, March 3, 2014.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AmpliPhi Biosciences Closes $18 Million Private Placement
Business Wire - Tue Dec 24, 6:30AM CST
AmpliPhi BioSciences Corporation (OTCBB:APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has completed the sale of approximately $18 million of common stock in a private placement financing. The Company has issued an aggregate of 72,007,000 shares of the Company's common stock at a price per share of $0.25. Net proceeds from the placement are approximately $16.9 million.
AmpliPhi Biosciences Announces $18 Million Private Placement
Business Wire - Mon Dec 16, 6:30AM CST
AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a private placement financing. Pursuant to the stock purchase agreement, the Company will issue an aggregate of 72,003,000 shares of the Company's common stock at a price per share of $0.25. Estimated net proceeds from the placement will be $16.9 million.
AmpliPhi Presents Data on Bacteriophages in the Treatment of Lung Infections in Cystic Fibrosis
Business Wire - Wed Aug 07, 11:01PM CDT
AmpliPhi BioSciences Corp. (OTC: APHB) ("AmpliPhi"
, the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the treatment of Pseudomonas aeruginosa (P. aeruginosa) at the 20th Biennial Evergreen International Phage Meeting held in Olympia, Washington, USA. P. aeruginosa is the major cause of lung infections in cystic fibrosis (CF) patients.
Huntingtons Disease Therapeutics - 2013 Global Strategic Business Report
M2 - Fri Aug 02, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnkpxr/huntingtons#summary) has announced the addition of the "Huntingtons Disease Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Huntingtons Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Hd Therapeutics Market Trends 3. Hd Research And Drug Pipeline 4. Research Breakthroughs In Hd Arena 5. An Overview Of Huntington's Disease 6. Clinical Trials 7. Recent Industry Activity 8. Corporate Activity In The Recent Past - A Perspective Builder 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Europe 3. Rest Of World IV. Competitive Landscape Companies Mentioned The report profiles 35 companies including - Alnylam Pharmaceuticals - AmpliPhi Biosciences Corp. - Ceregene - Cortex Pharmaceuticals - Intellect Neurosciences Incorporation - Prana Biotechnology Limited - Raptor Pharmaceuticals Corp. - Teva Pharmaceutical Industries Ltd. - Trophos SA - Valeant Pharmaceuticals International - Vertex Pharmaceuticals Incorporated. For more information, including full list of companies profiled, please visit http://www.researchandmarkets.com/research/tn...ns#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections
Business Wire - Mon Jul 01, 6:00AM CDT
AmpliPhi BioSciences Corporation (OTC:APHB) ("AmpliPhi" , the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced today a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR).
AmpliPhi Closes $7 Million Private Placement
Business Wire - Thu Jun 27, 7:30AM CDT
AmpliPhi BioSciences Corp. (OTC:APHB), the world leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today the completion of a successful private placement of convertible preferred stock with gross proceeds of $7 million. The financing was led by established life-sciences investors RA Capital Management and Third Security, LLC, with participation from BioScience Managers Pty Ltd.
AmpliPhi Establishes Collaboration with Intrexon
Business Wire - Tue Apr 16, 7:11AM CDT
AmpliPhi BioSciences Corp. (OTC: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, and Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, today announced the formation of an exclusive channel collaboration ("ECC" to develop new bacteriophage-based therapies to target specific antibiotic resistant infections, some of the most widespread and deadly types of infections.
AmpliPhi Receives Notice of Allowance on Key Patent for its Bacteriophage Therapy to Treat Drug-resistant Biofilm-based Infections
Business Wire - Mon Feb 04, 6:00AM CST
AmpliPhi Biosciences Corporation [APHB.PK] ("Ampliphi" (OTCBB:APHB), the anti-infective company focused on developing phage-based therapies to combat the growing threat of antibiotic-resistant infection, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 13/333,684 entitled "Bacteriophage-Containing Therapeutic Agents".
Retinal Degeneration - Pipeline Review, H1 2014
M2 - Wed Jul 30, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3mjdx6/retinal) has announced the addition of the "Retinal Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Degeneration - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Degeneration and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Mentioned: - AmpliPhi Biosciences Corporation - SanBio, Inc. - to-BBB technologies BV - Aprogen, Inc. - X-BODY BioSciences, Inc. - GenSight Biologics - Spark Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/3mjdx6/retinal
AmpliPhi to Present at 13th Annual Needham Healthcare Conference
Business Wire - Tue Apr 01, 7:01AM CDT
AmpliPhi BioSciences Corporation. (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that Philip Young, President and CEO, will be presenting a corporate overview at the 13th Annual Needham Healthcare Conference on Tuesday, April 08 at 8:40am EDT at the Westin NY Grand Central Hotel in New York, NY.
AmpliPhi to Present at Upcoming Healthcare Conferences
Business Wire - Wed Feb 26, 6:30AM CST
AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34th Annual Healthcare Conference at the Boston Marriott Copley Place Hotel in Boston at 2:50 pm EST (11:50 am PST) on Monday, March 3, 2014.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AmpliPhi Biosciences Closes $18 Million Private Placement
Business Wire - Tue Dec 24, 6:30AM CST
AmpliPhi BioSciences Corporation (OTCBB:APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has completed the sale of approximately $18 million of common stock in a private placement financing. The Company has issued an aggregate of 72,007,000 shares of the Company's common stock at a price per share of $0.25. Net proceeds from the placement are approximately $16.9 million.
AmpliPhi Biosciences Announces $18 Million Private Placement
Business Wire - Mon Dec 16, 6:30AM CST
AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a private placement financing. Pursuant to the stock purchase agreement, the Company will issue an aggregate of 72,003,000 shares of the Company's common stock at a price per share of $0.25. Estimated net proceeds from the placement will be $16.9 million.
AmpliPhi Presents Data on Bacteriophages in the Treatment of Lung Infections in Cystic Fibrosis
Business Wire - Wed Aug 07, 11:01PM CDT
AmpliPhi BioSciences Corp. (OTC: APHB) ("AmpliPhi"
, the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the treatment of Pseudomonas aeruginosa (P. aeruginosa) at the 20th Biennial Evergreen International Phage Meeting held in Olympia, Washington, USA. P. aeruginosa is the major cause of lung infections in cystic fibrosis (CF) patients. Huntingtons Disease Therapeutics - 2013 Global Strategic Business Report
M2 - Fri Aug 02, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnkpxr/huntingtons#summary) has announced the addition of the "Huntingtons Disease Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Huntingtons Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Hd Therapeutics Market Trends 3. Hd Research And Drug Pipeline 4. Research Breakthroughs In Hd Arena 5. An Overview Of Huntington's Disease 6. Clinical Trials 7. Recent Industry Activity 8. Corporate Activity In The Recent Past - A Perspective Builder 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Europe 3. Rest Of World IV. Competitive Landscape Companies Mentioned The report profiles 35 companies including - Alnylam Pharmaceuticals - AmpliPhi Biosciences Corp. - Ceregene - Cortex Pharmaceuticals - Intellect Neurosciences Incorporation - Prana Biotechnology Limited - Raptor Pharmaceuticals Corp. - Teva Pharmaceutical Industries Ltd. - Trophos SA - Valeant Pharmaceuticals International - Vertex Pharmaceuticals Incorporated. For more information, including full list of companies profiled, please visit http://www.researchandmarkets.com/research/tn...ns#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections
Business Wire - Mon Jul 01, 6:00AM CDT
AmpliPhi BioSciences Corporation (OTC:APHB) ("AmpliPhi"
, the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced today a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR). AmpliPhi Closes $7 Million Private Placement
Business Wire - Thu Jun 27, 7:30AM CDT
AmpliPhi BioSciences Corp. (OTC:APHB), the world leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today the completion of a successful private placement of convertible preferred stock with gross proceeds of $7 million. The financing was led by established life-sciences investors RA Capital Management and Third Security, LLC, with participation from BioScience Managers Pty Ltd.
AmpliPhi Establishes Collaboration with Intrexon
Business Wire - Tue Apr 16, 7:11AM CDT
AmpliPhi BioSciences Corp. (OTC: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, and Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, today announced the formation of an exclusive channel collaboration ("ECC"
to develop new bacteriophage-based therapies to target specific antibiotic resistant infections, some of the most widespread and deadly types of infections. AmpliPhi Receives Notice of Allowance on Key Patent for its Bacteriophage Therapy to Treat Drug-resistant Biofilm-based Infections
Business Wire - Mon Feb 04, 6:00AM CST
AmpliPhi Biosciences Corporation [APHB.PK] ("Ampliphi"
(OTCBB:APHB), the anti-infective company focused on developing phage-based therapies to combat the growing threat of antibiotic-resistant infection, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 13/333,684 entitled "Bacteriophage-Containing Therapeutic Agents". 
